Other Diseases

BioNTech lines up USD 800 Million for fuelling mRNA R&D BioNTech is lining up a Nasdaq IPO that raises USD 800 million. The German mRNA specialist is contemplating to stimulate its cash-intensive plans. BioNTech has booked Bank of America and JPMorgan with a plan to list on Nasdaq. The current plan is to increase to USD 800 million at a valuation of USD 4 billion. Deerfield remunerates USD 100 Million for research of translational agreement Deerfield Management and Harvard University are collaborating on translational R&D to pave the way to the clinic for new therapies discovered at Harvard. The duo is establishing a new company named as Lab1636, wi...